 |
Home > Patient Care > Find a Physician > Michael R. Grever
Michael R. Grever, MD
Chair, Department of Internal Medicine
Associate Dean for Medical Services
Professor of Internal Medicine
College of Medicine & Public Health
Charles A. Doan Chair of Medicine
Co-Program Leader, Experimental Therapeutics
for the James Comprehensive Cancer Center
Office
215 Means Hall
1654 Upham Drive
Columbus, OH 43210
Phone: (614) 293-8724
Fax: (614) 293-6656 Education
B.S., University of Pittsburgh 1967
M.D., University of Pittsburgh 1971 Post-doctoral Training
Internship: Presbyterian University Hospital 1971-1972
Residency: Presbyterian University Hospital 1972-1974
Fellowship: The Ohio State University,
Division of Hematology and Oncology 1976-1978 Recent Publications Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002 Apr;8(4):963-70. Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D’Ambrosio S, Gibson-D’Ambrosio R, Chan K. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol, 49(5):367-374, 2002. Liu J, Kraut EH, Balcerzak S, Grever MR, D’Ambrosio S, Chan KK. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother Pharmacol, 50(6):445-453, 2002. Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 101(2):425-432, 2003. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase-8-mediated apoptosis and downregulation of c-FLIP protein. Blood. 2003 Mar 20, (epub ahead of print). Byrd JC, Lucas DM, Mone A, Kitner JB, Drabick JJ, Grever MR. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood. 2003 Feb 20, (epub ahead of print). Xiao JJ, Byrd J, Marcucci G, Grever M, Chan K. Identification of thiols and glutathione conjugates of depsipeptide FD228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Comm. Mass Spectrom. 2003;17:757-766 Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia. 2003 Feb;17(2):350-8
|
